Format

Send to

Choose Destination
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1477-84. doi: 10.1016/j.ijrobp.2008.04.020.

Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.

Author information

1
Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA. newcoe01@med.nyu.edu

Erratum in

  • Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):655-6.

Abstract

PURPOSE:

To assess the effects of noscapine, a tubulin-binding drug, in combination with radiation in a murine glioma model.

METHODS AND MATERIALS:

The human T98G and murine GL261 glioma cell lines treated with noscapine, radiation, or both were assayed for clonogenic survival. Mice with established GL261 hind limb tumors were treated with noscapine, radiation, or both to evaluate the effect of noscapine on radioresponse. In a separate experiment with the same treatment groups, 7 days after radiation, tumors were resected and immunostained to measure proliferation rate, apoptosis, and angiogenic activity.

RESULTS:

Noscapine reduced clonogenic survival without enhancement of radiosensitivity in vitro. Noscapine combined with radiation significantly increased tumor growth delay: 5, 8, 13, and 18 days for control, noscapine alone, radiation alone, and the combination treatment, respectively (p < 0.001). To assess the effect of the combination of noscapine plus radiation on the tumor vasculature, tubule formation by the murine endothelial 2H11 cells was tested. Noscapine with radiation significantly inhibited tubule formation compared with radiation alone. By immunohistochemistry, tumors treated with the combination of noscapine plus radiation showed a decrease in BrdU incorporation, an increase in apoptosis by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling, and a decrease in tumor vessel density compared with tumors treated with radiation alone.

CONCLUSION:

Noscapine enhanced the sensitivity of GL261 glioma tumors to radiation, resulting in a significant tumor growth delay. An antiangiogenic mechanism contributed to the effect. These findings are clinically relevant, particularly in view of the mild toxicity profile of this drug.

PMID:
18640497
PMCID:
PMC2572218
DOI:
10.1016/j.ijrobp.2008.04.020
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center